SCHEMBL2328394

SCHEMBL2328394

O=C(SS)C(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
CTSD P07339 1/20 0.47
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.45
CYP2D6 P10635 1/20 0.44
SRC P12931 1/20 0.44
LMNA P02545 2/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2328390 0.81 TDP1 (0.54) TDP1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL5565862 0.77 POLB (0.50) TDP1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL3448890 0.73 HSD11B1 (0.59) TDP1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL465969 0.72 TDP1 (0.61) TDP1L3MBTL1HDAC3HDAC4HDAC1
Diphenylacetic Acid SCHEMBL8513250 0.72 SRC (0.62) TDP1L3MBTL1HDAC3HDAC4HDAC1
Diphenylacetic Acid SCHEMBL38022 0.72 SRC (0.62) TDP1L3MBTL1HDAC3HDAC4HDAC1
Diphenylacetic Acid SCHEMBL8411440 0.70 SRC (0.59) TDP1L3MBTL1HDAC3HDAC4HDAC1
Diphenylacetic Acid SCHEMBL9485695 0.70 SRC (0.59) TDP1L3MBTL1HDAC3HDAC4HDAC1
Diphenylacetic Acid SCHEMBL418537 0.70 SRC (0.59) TDP1L3MBTL1HDAC3HDAC4HDAC1
SCHEMBL72488 0.70 TDP1 (0.58) TDP1L3MBTL1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119899356-A Self-healing polyurethane elastomer material based on dynamic reversible covalent bonds, preparation method and seamless telescopic structure based on material 南京兴佑交通科技有限公司 2025-04-29 CN claimed
CN-118304462-B Hemostatic material and preparation method thereof 安徽皓元药业有限公司 2024-08-16 CN claimed
CN-118304462-A Hemostatic material and preparation method thereof 安徽皓元药业有限公司 2024-07-09 CN claimed
WO-2026102761-A1 XDH NUCLEIC ACID-TARGETED OLIGONUCLEOTIDE AND USE THEREOF 思合基因(北京)生物科技有限公司 2026-05-21 WO disclosed
CN-122038392-A Antisense oligonucleotide targeting ACSL4 mRNA and application thereof in preparation of hypolipidemic drugs 云南大学 2026-05-15 CN disclosed
CN-122055446-A IRS-1 mRNA targeting oligonucleotide and application thereof 思合基因(北京)生物科技有限公司 2026-05-15 CN disclosed
CN-121045299-A Oligonucleotide synthesis method 通用生物(安徽)股份有限公司 2025-12-02 CN disclosed
CN-119899356-A Self-healing polyurethane elastomer material based on dynamic reversible covalent bonds, preparation method and seamless telescopic structure based on material 南京兴佑交通科技有限公司 2025-04-29 CN disclosed
CN-119876147-A Oligonucleotides for inhibiting TRPV1 expression, composition and application 思合基因(北京)生物科技有限公司 2025-04-25 CN disclosed
CN-119752901-A CpG oligonucleotide 浙江天元生物药业有限公司 2025-04-04 CN disclosed
CN-119662638-A Double-stranded RNA composition for regulating expression of angiotensinogen AGT and application thereof 苏州时安生物技术有限公司 2025-03-21 CN disclosed
WO-2010039088-A1 CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS AHMED KARIEM (SE) 2010-04-08 WO disclosed
US-20100016416-A1 Oligonucleotide Conjugates GERON CORPORATION (US) 2010-01-21 US disclosed
US-7563618-B2 Oligonucleotide conjugates GERON CORPORATION (US) 2009-07-21 US disclosed
EP-1543021-A2 OLIGONUCLEOTIDE CONJUGATES Geron Corporation (US) 2005-06-22 EP disclosed
EP-1379689-A4 OLIGONUCLEOTIDE CONJUGATES GERON CORP (US) 2004-04-14 EP disclosed
WO-2004029277-A2 OLIGONUCLEOTIDE CONJUGATES GERON CORPORATION (US) 2004-04-08 WO disclosed
EP-1379689-A2 OLIGONUCLEOTIDE CONJUGATES Geron Corporation (US) 2004-01-14 EP disclosed
US-20030138814-A1 Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) GERON CORPORATION 2003-07-24 US disclosed
WO-2002077184-A2 OLIGONUCLEOTIDE CONJUGATES GERON CORPORATION (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030138814-A1 Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) TERT, RNGTT, DUT TDP1 170/4885L3MBTL1 230/4885HDAC3 1211/4885
US-20100016416-A1 Oligonucleotide Conjugates TERT, RNGTT, TRDMT1 TDP1 51/4885L3MBTL1 318/4885HDAC3 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.